i-LAB

UnknownPhase 3

Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans

Lead sponsor

University of Campinas, Brazil

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

Estimated enrollment

Study population

Obesity / overweight

Eligibility highlights

•BMI ≥30

Primary endpoint

•Evaluate the effect of liraglutide administration on brown adipose tissue (BAT)

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02718950

Org study IDi-LAB

Secondary IDU1111-1178-4180Universal Trial Number

Timeline

Milestones

Study first posted2016-03-24estimated

Last update posted2016-03-24estimated

Study start2016-06 (month precision)

Primary completion2017-03estimated (month precision)

Study completion2017-04estimated (month precision)

Assets

Investigational agents

Liraglutide

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years

Maximum age65 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Body mass index over 30 kg/m2.

Exclusion criteria

•Hypersensitivity to liraglutide or any of its vehicle components;

•History of diabetes or pre-diabetes - either by fasting glycemia, oGTT or HbA1c;

•Previous treatment within the last 3 months with glucagon like peptide-1 agonists, iDPP4 or any medication that is associated with BAT activation, including propranolol and benzodiazepines;

•Liver diseases, except non-alcoholic steatohepatitis (NASH);

•Infection by HIV, hepatitis B or hepatitis C;

•Addiction to cannabis, heroin, morphine, cocaine, benzodiazepines or amphetamine;

•Obesity induced by other disorders such as Cushing syndrome, hypothyroidism, lipodystrophy

•Current or history of treatment with medications that may cause significant weight gain within 3 months prior to screening, including systemic corticosteroids (except for a short course of treatment, i.e. 7-10 days), tricyclic antidepressants, atypical antipsychotic and mood stabilizers (e.g. imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid and its derivatives, and lithium);

•Current participation (or within the last 3 months) in an organized weight reduction program

•Currently or previous using within 3 months before screening of pramlintide, sibutramine, orlistat, topiramate, or metformin (either by prescription or as part of a clinical trial)

•Participation in a clinical trial within the last 3 months prior to screening

•Simultaneous participation in any other clinical trial of an investigational drug

•Previous surgical treatment of obesity;

•Cancer (past or present, except basal cell skin cancer or squamous cell skin cancer), which in the investigator's opinion could interfere with the results of the trial

•Liver enzyme (ALT and AST) above 2.5 x of reference range

•Pancreatic enzymes (amylase, lipase) above 3 x the reference range

•Chronic kidney disease stages 3, 4, or 5

•Relevant inflammatory or acute or chronic infectious disease; hyperthyroidism; neurological, psychiatric, gastrointestinal, respiratory, renal, hepatic or cardiac relevant disease, that could interfere with trial results per the judgment of investigator

•Any condition that at the discretion of investigator could interfere with treatment adhesion on patient safety

•Blood donation or transfusion within the last 3 months

•Pregnancy or intention of pregnancy

•History of Multiple Endocrine Neoplasia Syndrome Type 2 (MEN 2)

•History of pancreatitis

•Less than 80% of liraglutide adherence

•Calcitonin above the reference range at the screening visit.

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Other (unclassified)

Weight & body composition

3 endpoints

Primary/protocol endpoint/low confidence

Evaluate the effect of liraglutide administration on brown adipose tissue (BAT) activation in humans

Time frame:2 weeks

threshold achievement, improvement

Secondary/protocol endpoint

Evaluate the effect of liraglutide administration on body weight in humans

Time frame:2 weeks

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Evaluate the effect of liraglutide administration on body composition in humans

Time frame:2 weeks

Total fat mass

change from baseline, improvement

Other (unclassified)

3 endpoints

Secondary/protocol endpoint/low confidence

Evaluate the effect of liraglutide administration on hypothalamic activation in humans

Time frame:2 weeks

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

Evaluate the effect of liraglutide administration on non-shivering thermogenesis in humans

Time frame:2 weeks

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

Evaluate the effect of liraglutide administration on metabolic basal rate in humans

Time frame:2 weeks

change from baseline, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.